These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17166669)

  • 1. Therapeutic possibilities of cysteamine in the treatment of schizophrenia.
    Pae CU; Lee C; Paik IH
    Med Hypotheses; 2007; 69(1):199-202. PubMed ID: 17166669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels.
    Tsai SJ
    Med Hypotheses; 2006; 67(5):1185-8. PubMed ID: 16797865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex.
    Pillai A; Veeranan-Karmegam R; Dhandapani KM; Mahadik SP
    J Neurochem; 2008 Nov; 107(4):941-51. PubMed ID: 18786174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D3 receptor and schizophrenia: a widened scope for the immune hypothesis.
    Vogel M; Busse S; Freyberger HJ; Grabe HJ
    Med Hypotheses; 2006; 67(2):354-8. PubMed ID: 16540254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemistry and the schizophrenia. Old concepts and new hypothesis.
    Berger PA
    J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critique of the dopamine hypothesis of schizophrenia and psychosis.
    Moncrieff J
    Harv Rev Psychiatry; 2009; 17(3):214-25. PubMed ID: 19499420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BDNF in schizophrenia, depression and corresponding animal models.
    Angelucci F; Brenè S; Mathé AA
    Mol Psychiatry; 2005 Apr; 10(4):345-52. PubMed ID: 15655562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice.
    Shieh CH; Hong CJ; Huang YH; Tsai SJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1590-4. PubMed ID: 18582526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central dopaminergic mechanisms in schizophrenia.
    Owen F; Crow TJ; Poulter M
    Acta Psychiatr Belg; 1987; 87(5):552-65. PubMed ID: 2897760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does neurotropin-3 have a therapeutic implication in major depression?
    Pae CU; Marks DM; Han C; Patkar AA; Steffens D
    Int J Neurosci; 2008 Nov; 118(11):1515-22. PubMed ID: 18853330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
    Goto Y; Grace AA
    Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder.
    Gama CS; Andreazza AC; Kunz M; Berk M; Belmonte-de-Abreu PS; Kapczinski F
    Neurosci Lett; 2007 Jun; 420(1):45-8. PubMed ID: 17442489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurobiology of dopamine in schizophrenia.
    Guillin O; Abi-Dargham A; Laruelle M
    Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.